Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance).
Federico InnocentiAlexander B SibleySushant A PatilAmy S EtheridgeChen JiangFang-Shu OuStefanie D HowellSarah J PlummerGraham CaseyMonica M BertagnolliHoward L McLeodJames T AumanCharles D BlankeYoichi FurukawaAlan P VenookMichiaki KuboHeinz-Josef LenzJoel S ParkerMark J RatainKouros OwzarPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
This is the first large genome-wide association study ever conducted in patients with mCRC treated with first-line standard treatment in a randomized phase III trial. A common SNP in AXIN1 conferred worse OS and the effect was replicated in TCGA. Further studies in colorectal cancer experimental models are required.
Keyphrases
- phase iii
- genome wide association study
- open label
- clinical trial
- phase ii
- double blind
- placebo controlled
- genome wide
- dna repair
- study protocol
- squamous cell carcinoma
- locally advanced
- randomized controlled trial
- oxidative stress
- radiation therapy
- dna methylation
- newly diagnosed
- combination therapy
- case control
- high density
- genetic diversity